BBOT

1.8102.69%
PP

Praveen P. Tipirneni

Independent Director

Dr. Praveen P. Tipirneni, M.D., M.B.A., is the Chief Executive Officer, Secretary and Director at Caldera Therapeutics. At Cubist, he was head of business development since January 2006. He serves as Director at Soufflé Therapeutics, Inc. He is Chairman of the Board of Tasca Therapeutics Corp. He is Executive Chairperson of SiteOne Therapeutics, Inc. from December 2024. He has been Independent Director at Tectonic Therapeutic, Inc since February 2020. He is Independent Non-Executive Director of BridgeBio Oncology Therapeutic Inc. (also known as TheRas, Inc) since November 2024. He serves as an Independent Director at Panacea Acquisition Corp. II since April 6, 2021. He serves as Chief Executive Officer at Morphic Therapeutics, Inc and Director at Tectonic Therapeutic, Inc. Praveen serves as Venture partner at Atlas Venture Advisors, Inc. (formerly known as Atlas Venture L.P.). since 2024. He has been Chief Executive Officer and Director of Morphic Holding, Inc. since July 2015 and served as President since July 2015. Dr. Tipirneni serves as Chief Executive Officer and President of Morphic Rock Therapeutic, Inc. Dr. Tipirneni served as Senior Vice President of Corporate Development and Global Strategy at Cubist Pharmaceuticals Inc. from 2002 till February 2015 and served as its Vice President of Business Development since January 2006. Dr. Tipirneni operated in both the Business Development and Clinical Development functions. Dr. Tipirneni worked at Sun Microsystems in Corporate Strategy, Covad Communications in Corporate Strategy and Deltagen in business development and also served time as 1st Lieutenant in the U.S. Army. Dr. Tipirneni holds B.A. from MIT in Mechanical Engineering, an M.D. from McGill University Faculty of Medicine. After completing his post-graduate residency in Internal Medicine at University of Illinois, Chicago, he received MBA from the University of Pennsylvania's Wharton School of Business in Healthcare Finance.

Positions